Sander J Hogewoning

Sander J Hogewoning

Auto-generated profile, based on publicly available information

Sander J Hogewoning

Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2021 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
PDF file
TSTessa G Steenbruggen
Tessa G Steenbruggen
MSMichael Schaapveld
Michael Schaapveld
HHHugo M Horlings
Hugo M Horlings
JSJoyce Sanders
Joyce Sanders
SHSander J Hogewoning
Sander J Hogewoning
GSGabe S Sonke
Gabe S Sonke
Observational studies in metastatic breast cancer (MBC) show that long-term overall survival (OS) is associated with limited tumor burden, or oligo-MBC (OMBC). However, a uniform definition of OMBC is lacking. In this real-world nationwide cohort, we aimed to define the optimal OMBC threshold and factors associated with survival in patients with OMBC. 3535 patients aged younger than 80 years at diagnosis of de novo MBC in the Netherlands between January 2000 and December 2007 were included. Detailed clinical, therapy, and outcome data were collected from medical records of a sample of the patients. Using inverse-sampling-probability weighting, the analysis cohort (n = 3447) was constructed. We assessed OS according to number of metastases at diagnosis to determine the optimal OMBC threshold. Next, we applied Cox regression models with inverse-sampling-probability weighting to study associations with OS and progression-free survival in OMBC. All statistical tests were 2-sided. Compared with more than 5 distant metastases, adjusted hazard ratios for OS (with 95% confidence interval [CI] based on robust standard errors) for 1, 2-3, and 4-5 metastases were 0.70 (95% CI = 0.52 to 0.96), 0.63 (95% CI = 0.45 to 0.89), and 0.91 (95% CI = 0.61 to 1.37), respectively. Ten-year OS estimates for patients with no more than 3 vs more than 3 metastases were 14.9% and 3.4% (P < .001). In multivariable analyses, premenopausal andperimenopausal status, absence of lung metastases, and local therapy of metastases (surgery and/or radiotherapy) added to systemic therapy were statistically significantly associated with better OS and progression-free survival in OMBC, independent of local therapy of the primary tumor. OMBC defined as MBC limited to 1-3 metastases was associated with favorable OS. In OMBC, local therapy of metastases was associated with better OS, particularly if patients were premenopausal or perimenopausal without lung metastases.

1 May 2018 in The Lancet Haematology
Verified
Journal Article
Closed access
SRSonja E van Roeden
Sonja E van Roeden
FHFedor van Houwelingen
Fedor van Houwelingen
CDChiel M J Donkers
Chiel M J Donkers
SHSander J Hogewoning
Sander J Hogewoning
MLMarit M A de Lange
Marit M A de Lange
JOJan Jelrik Oosterheert
Jan Jelrik Oosterheert

1 June 2000 in Journal of Radioanalytical and Nuclear Chemistry
Verified
Journal Article
Closed access
PDF file
SHS.J. Hogewoning
S.J. Hogewoning
PBP. Bode
P. Bode